57 results about "Osteoclast cell differentiation" patented technology

Disclosed herein is a matrix for inducing or enhancing osteoclast differentiation. The matrix comprises a material having an osteoclastogenic agent associated therewith, the agent being releasable from the material in an amount which is sufficient to induce or enhance osteoclast differentiation.

A protein which inhibits osteoclast differentiation and / or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

The present invention provides a RANK (receptor activator of NF-kappaB) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The decoy peptide inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.

The invention belongs to the field of cell extraction and differentiation authentication, and discloses a method for extracting myelomonocyte and differentiating to osteoclast. The method comprises the following steps: (A) performing sterile myelomonocyte separation, culturing in a complete medium of 20-100ng / mLM-CSF, replacing the complete medium every other day, and observing the morphological characteristics of monocyte; (B) when the density of monocyte is 80-90%, taking out a part of the cells for surface antigen authentication; (C) drawing a growth curve of other cells and performing differentiation induction for osteoclast on other cells. The method for extracting myelomonocyte and differentiating to osteoclast is simple, convenient and reliable, low in requested condition requirements, low in cost and short in time, the extracted monocyte is stable in property, and C57BL / 6 mice myelomonocyte which is reliable and stable in resource can be provided for medical basis, clinical research, tissue engineering study, and the like.

Disclosed is an osteoblast differentiation promoting and osteoclast differentiation inhibiting agent which comprises a milk protein fraction having the following characteristics (1) to (4): (1) the milk protein fraction is derived from milk; (2) the milk protein fraction is a fraction containing a protein component having a molecular weight of 75,000 to 85,000 Daltons; (3) the milk protein fraction has a basic amino acid content of 13 to 15 wt % in the constitutional amino acid composition, and has a basic amino acid / acidic amino acid of 0.5 to 0.7; and (4) the milk protein fraction has an osteoblast differentiation promoting effect and an osteoclast differentiation inhibiting.

The invention provides application of mircoRNA. The microRNA can be used in the preparation of a medicine for inhibiting osteoclast differentiation and bone destruction. The microRNA is selected frommiR-17, miR-20a and miR-92a. Sequence of the miR-17 is as shown in the SEQ ID NO:1. Sequence of the miR-20a is as shown in the SEQ ID NO:2. Sequence of the miR-92a is as shown in the SEQ ID NO:3. As upregulation of miR-17, miR-20a or miR-92a in the microRNA has an effect of inhibiting osteoclast differentiation, the microRNA can be used as a new therapeutic target for regulating bone metabolism.

The invention discloses application of 2-bromopalmitate (2-BP) in preparation of drugs for prevention and treatment of bone loss related diseases, and belongs to the technical field of medicine. The invention, for the first time, clearly defines that 2-BP can inhibit osteoclast differentiation process of BMMs stimulated by RANKL through various experimental techniques, including tartrate resistantacid phosphatase staining, phalloidin fluorescence staining, bone lamella bone resorption function evaluation, reverse transcription real-time fluorescence quantitative PCR, Western blot, etc. In addition, the invention clearly states that 2-BP also has effects in inhibiting osteoclast differentiation and activation in vivo, and 2-BP can significantly alleviate the pathological process of massivebone loss caused by estrogen deficiency through the establishment of a mouse model of ovariectomy-induced osteoporosis, thus providing experimental data basis in vivo for the role of 2-BP in the prevention and treatment of bone loss related diseases.

The invention discloses an application of a cyclic polypeptide CST-14 in preparation of a drug for treating osteoporosis. The CST-14 can be directly combined with a key receptor RANK in an osteoporosis process to antagonize an osteoclast induction function caused by RANKL and to play a protective role in the osteoporosis. An in vitro cell experiment result shows that the CST-14 can antagonize an osteoclast differentiation process caused by an osteoporosis key molecule RANKL. Meanwhile, an animal model shows that the CST-14 can inhibit the occurrence of the osteoporosis and improve disease conditions, does not have obvious toxic and side effects after long-term use, can be applied to the field of osteoporosis treatment and has broad application value and market prospect.

The invention discloses a new application of aurantiamide alcohol ester as an MMP-9 inhibitor. Under the condition that the aurantiamide alcohol ester has no cytotoxicity to osteoclast precursor cellsRAW 264.7, the capability of differentiation of RAW 264.7 cells induced by RANKL into osteoclasts is remarkably inhibited, and a certain concentration dependence is shown; follow-up research finds that the aurantiamide alcohol ester significantly reduces the expression of MMP-9 in the osteoclast formation process, thereby inhibiting osteoclast differentiation and formation. The invention discloses the application of the aurantiamide alcohol ester in preventing and treating osteolytic diseases, wherein the aurantiamide alcohol ester can be used for preventing and treating osteolytic diseases including bone destruction, osteoporosis and the like together with a medicine prepared from a conventional medicinal carrier. The invention provides a new medicine for preventing and treating osteoporosis, and has a great clinical application value.

The invention discloses an application of a substituted guanidyl-containing derivative in preparation of an osteoclast differentiation inhibitor. The substituted guanidyl-containing derivative has a direct and remarkable inhibition effect on RANKL-induced osteoclast differentiation and bone resorption activity, so that the substituted guanidyl-containing derivative can be used as an osteoclast differentiation inhibitor drug for treating diseases treated by an osteoclast differentiation inhibitor.

The invention relates to medicine application, and specifically discloses application of acrylophenone amide derivates to the preparation of anti-osteoporosis medicine. The structural formula of the acrylophenone amide derivates is shown as formula (I) or formula (II). The compound is different from a molecular skeleton of medicine for preventing and treating osteoporosis used clinically at present, does not belong to a phosphate compound, and is neither estrogen medicine. Cytology experiment researches indicate that the compound can inhibit osteoclast differentiation so as to be of an anti-osteoporosis effect; cytotoxicity tests indicate that the compound is little in toxicity, and can be used for preventing and treating related diseases, particularly osteoporosis, caused by osteoclast prosoplasia.

Provided is a purified, negative regulator of osteoclast differentiation and bone resorption, specifically LRRc17. Further provided are methods and compositions for treating degenerative bone disorders, and treatments and prophylactic approaches for regulating bone resorption, and for decreasing or inhibiting the excessive bone loss associated with abnormal or excessive generation of or activity of osteoclasts.

The invention relates to application of recombinant IFN-lambda1 protein in preparation of a medicine for preventing and treating inflammation-induced bone loss, thereby solving a problem of bone metabolism imbalance caused by overactive osteoclasts triggered by release of a large number of inflammatory factors in a serious inflammatory bone loss state caused by bone infection. The applicant findsthat the recombinant IFN-lambda 1 protein can regulate and control the osteoclast differentiation and fusion process and reduce inflammatory factor release in the osteoclast differentiation process through experimental exploration, thereby solving a problem that osteoclasts are excessively activated in an inflammatory state and thus realizing the effect of protecting inflammatory bone loss.

The present invention provides a reagent containing a fused protein of RANKL with an epitope tag that has improved effects of differentiating and activating osteoclasts and improved preservation stability compared with the case of using RANKL alone, and an agent for differentiating and activating osteoclasts that can be used in vitro or in vivo, containing, as an active ingredient, a fused protein of soluble RANKL with an epitope tag peptide.

The invention discloses application of graphene quantum dots to prevention and treatment of osteoporosis. The application of the graphene quantum dots to prevention and treatment of osteoporosis concretely comprises application of the graphene quantum dots to preparation of a drug for inhibiting fusion or differentiation and maturation of osteoclast precursor cells, application of the graphene quantum dots to preparation of a drug for resisting the bone resorption capacity of mature osteoclast, application of the graphene quantum dots to preparation of a drug for inhibiting differentiation and fusion of osteoclast or expression of ripening-associated genes, application of the graphene quantum dots to preparation of a drug for inhibiting TRAP enzyme activity of osteoclast, and application of the graphene quantum dots to preparation of a drug for inhibiting fusion of osteoclast precursor cells to form multinucleated mature osteoclast; an effective dose of the graphene quantum dots can inhibit differentiation and maturation of RANKL induced BMMs cells to osteoclast in a concentration-dependent manner, inhibit bone resorption capacity of osteoclast obtained by differentiation and maturation of the RANKL induced BMMs cells, and further inhibit fusion of osteoclast; besides, the graphene quantum dots can obviously reduce expression of osteoclast differentiation specific genes, therefore the graphene quantum dots finally achieve the function of preventing and treating osteoporosis, and further can be applied to prevention and treatment of osteoporosis.

The invention relates to application of erianin in preparation of an osteoclast differentiation inhibitor. Experiments prove that low-dose erianin can significantly inhibit RANKL and breast cancer induced mouse osteoclast generation and bone resorption activity; meanwhile, low-dose erianin can inhibit osteoclast precursor cells of a patient with breast cancer bone metastasis from generating polykaryotic osteoclasts, so that erianin can be used as an osteoclast differentiation inhibitor drug for treating diseases by an osteoclast differentiation inhibitor. The invention provides a new application of erianin, and also provides a new thought for treating bone destruction related diseases, tumor-induced bone destruction and other diseases.

The invention discloses application of a Flot2 inhibitor to inhibition of osteoclast formation and / or osteoclastic activity for the first time. The osteoclast generation and bone resorption induced byRANKL can be obviously reduced after the Flot2 expression is inhibited by Flot2-siRNA specific interference. A study team of the inventor discovers that the Flot2 directly participates in the osteoclast generation and bone resorption functions, and is possible to become a novel target of an osteoclast differentiation inhibitor. On the basis of the inhibition effect of Flot2-siRNA on osteoclasts and the application prospects of RNA interference medicine, the application of the Flot2 inhibitor as a medicine of inhibiting the osteoclast generation is provided.

The invention discloses a mutant protein of osteoprotegerin, as well as a relevant product and application thereof. When the mutant protein of the osteoprotegerin is compared with wild osteoprotegerin, a 73rd amino acid residue of a full-length sequence of the wild osteoprotegerin is substituted; the mutant protein has affinity activity for RANKL (Receptor Activator of NF-kappaB ligand), but the affinity activity of the mutant protein for TRAIL is lower than that of the wild osteoprotegerin. As proved by experiments, compared with the corresponding wild osteoprotegerin, the mutant protein of the osteoprotegerin provided by the invention has the advantages that no significant difference exists in the capability of inhibiting RANKL induced osteoclast cell differentiation, the defect that theanti-tumor effect of TRAIL is inhibited by the wild osteoprotegerin can be overcome, and the effect of preventing and treating bone resorption related diseases is achieved more efficiently and safely.

The invention belongs to the technical field of osteoclast activation mechanism measurement, and discloses a measurement method for regulating an osteoclast activation mechanism in osseous metastasis.The method includes the steps of collecting data information of the lungs by a lung detection instrument; regulating osteoclast activation in osseous metastasis by RANK-RANKL; extracting myelomoncytes and differentiating the myelomoncytes to osteoclasts; judging whether a patient suffers from osseous metastasis or not by screening. The method can realize identification of osseous metastasis and healthy osseous metastasis bone tissue samples directly without sample pretreatment or normal temperature and pressure conditions, and has the advantages of simple operation, high precision and the like; myelomoncytes and mesenchymal stem cells are separated out at the same time, and primary myelomoncytes obtained by separation and purification can be successfully changed into osteoclasts by induced differentiation; meanwhile, data obtained after pretreatment and feature extraction is subjected to classification training by screening, and whether the patient suffers from osseous metastasis or not can be more conveniently and quickly judged.

The invention discloses application of a pregnane derivative in preparation of an osteoclast differentiation inhibitor. According to the application of the pregnane derivative in preparation of the osteoclast differentiation inhibitor, the structural formula of the pregnane derivative is shown as a formula 1. It is found through tests that the pregnane derivative has a direct and remarkable inhibiting effect on osteoclast differentiation, and therefore the pregnane derivative can serve as an osteoclast differentiation inhibitor medicine to be used for treating various diseases such as osteoporosis caused by osteoclast differentiation.

The present invention discloses for the first time the application of Flot2 inhibitors in inhibiting osteoclast formation and / or osteoclast activity, and can significantly reduce RANKL-induced osteoclastogenesis and bone resorption after Flot2 expression is inhibited by specific interference of Flot2-siRNA. The inventor's research team found that Flot2 is directly involved in osteoclast formation and bone resorption, and may become a new target for osteoclast differentiation inhibitors. Based on the inhibitory effect of Flot2‑siRNA on osteoclasts and the application prospect of RNA interference drugs, the application of Flot2 inhibitors as drugs for inhibiting osteoclastogenesis is provided.

The invention discloses an application of vanilline in preparation of an osteoclast differentiation inhibitor. According to the application of the vanilline in preparation of the osteoclast differentiation inhibitor, wherein the structural formula of the vanilline is shown as a formula 1. It is found through tests that vanilline has a direct and remarkable inhibition effect on osteoclast differentiation, and therefore vanilline can serve as an osteoclast differentiation inhibitor medicine to be used for treating various diseases such as osteoporosis caused by osteoclast differentiation.

The invention discloses application of proteus mirabilis outer membrane vesicle in preparation of a medicine for preventing or treating osteolytic diseases. The proteus mirabilis outer membrane vesicle inhibits miR96-5p expression and promotes Abca1 expression, thereby inhibiting an MAPK / ERK pathway and causing osteoclast differentiation to be blocked; the proteus mirabilis outer membrane vesicle induces release of MPT-related cytochrome c to cause a mitochondrial structure to be damaged, increase production of active oxygen and cause increase of osteoclast apoptosis. The proteus mirabilis outer membrane vesicle not only significantly inhibits differentiation and functions of RANKL-induced osteoclasts in vitro, but also can improve bone metabolism imbalance caused by OVX and bone erosion caused by CII in vivo, and provides a new idea for preventing or treating the osteolytic diseases.

The invention relates to the application of vanillin in the preparation of medicines for treating / preventing bone metabolism diseases, through which vanillin inhibits the proliferation of osteoclasts, the formation of multinucleated mature osteoclasts and the osteophagic ability of osteoclasts, and promotes mature osteoclasts Apoptosis regulates osteoclast differentiation, fusion, maturation genes and related genes of apoptosis, which can maintain bone homeostasis, prevent bone loss, maintain bone density, and provide a therapeutic / preventive solution for diseases caused by osteoclast activity. new drug.